Characteristics of the study cohort (N = 4270)
| Characteristic . | n (%) . |
|---|---|
| Recipients genotyped | 3850 (90) |
| Donors genotyped | 3977 (93) |
| Patient age at transplantation, y | |
| Median | 43 |
| Range | 0-78 |
| Diagnosis | |
| Acute leukemia | 1761 (41) |
| Chronic myeloid leukemia | 1032 (24) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 736 (17) |
| Chronic lymphocytic leukemia | 116 (3) |
| Malignant lymphoma or multiple myeloma | 625 (15) |
| Disease risk* | |
| Low | 936 (22) |
| Intermediate | 1199 (28) |
| High | 1881 (44) |
| Not classified | 254 (6) |
| Donor-recipient sex combination | |
| Male to male | 1438 (34) |
| Male to female | 953 (22) |
| Female to male | 1038 (24) |
| Female to female | 839 (20) |
| Donor type | |
| Related HLA-A, -B, -C, -DRB1, or -DQB1 matched | 1855 (43) |
| HLA-DP mismatched† | 84 (5) |
| Related HLA-A, -B, -C, -DRB1, or -DQB1 mismatched | 130 (3) |
| HLA-DP mismatched† | 67 (52) |
| Unrelated HLA-A, -B, -C, -DRB1, or -DQB1 matched | 1447 (34) |
| HLA-DP mismatched† | 1117 (77) |
| Unrelated HLA-A, -B, -C, -DRB1, or -DQB1 mismatched | 838 (20) |
| HLA-DP mismatched† | 661 (79) |
| Graft source | |
| Bone marrow | 2325 (54) |
| Mobilized blood cells | 1945 (46) |
| T cell–depleted graft | 31 (1) |
| Conditioning regimen | |
| Myeloablative, <900 cGy TBI | 1515 (35) |
| Myeloablative, ≥900 cGy TBI | 2021 (47) |
| Nonmyeloablative | 734 (17) |
| Antithymocyte globulin | 55 (1) |
| Posttransplantation immunosuppression | |
| Cyclosporine or tacrolimus | 4139 (97) |
| Methotrexate or mycophenolate mofetil | 3926 (92) |
| Cyclophosphamide | 40 (1) |
| Characteristic . | n (%) . |
|---|---|
| Recipients genotyped | 3850 (90) |
| Donors genotyped | 3977 (93) |
| Patient age at transplantation, y | |
| Median | 43 |
| Range | 0-78 |
| Diagnosis | |
| Acute leukemia | 1761 (41) |
| Chronic myeloid leukemia | 1032 (24) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 736 (17) |
| Chronic lymphocytic leukemia | 116 (3) |
| Malignant lymphoma or multiple myeloma | 625 (15) |
| Disease risk* | |
| Low | 936 (22) |
| Intermediate | 1199 (28) |
| High | 1881 (44) |
| Not classified | 254 (6) |
| Donor-recipient sex combination | |
| Male to male | 1438 (34) |
| Male to female | 953 (22) |
| Female to male | 1038 (24) |
| Female to female | 839 (20) |
| Donor type | |
| Related HLA-A, -B, -C, -DRB1, or -DQB1 matched | 1855 (43) |
| HLA-DP mismatched† | 84 (5) |
| Related HLA-A, -B, -C, -DRB1, or -DQB1 mismatched | 130 (3) |
| HLA-DP mismatched† | 67 (52) |
| Unrelated HLA-A, -B, -C, -DRB1, or -DQB1 matched | 1447 (34) |
| HLA-DP mismatched† | 1117 (77) |
| Unrelated HLA-A, -B, -C, -DRB1, or -DQB1 mismatched | 838 (20) |
| HLA-DP mismatched† | 661 (79) |
| Graft source | |
| Bone marrow | 2325 (54) |
| Mobilized blood cells | 1945 (46) |
| T cell–depleted graft | 31 (1) |
| Conditioning regimen | |
| Myeloablative, <900 cGy TBI | 1515 (35) |
| Myeloablative, ≥900 cGy TBI | 2021 (47) |
| Nonmyeloablative | 734 (17) |
| Antithymocyte globulin | 55 (1) |
| Posttransplantation immunosuppression | |
| Cyclosporine or tacrolimus | 4139 (97) |
| Methotrexate or mycophenolate mofetil | 3926 (92) |
| Cyclophosphamide | 40 (1) |